Concepedia
Statistics
Publications
20
Citations
2K
H-Index
19
Active since
2002
Affiliations
Abbott Fund(Current)
AbbVie (United States)
Abbott (United Kingdom)
Abbott (United States)
Robin R. Frey is an author at Abbott Fund specializing in medicine, pharmacology, and drug discovery.
Top concepts
MedicinePharmacologyDrug DiscoveryBiochemistryNatural SciencesMedicinal ChemistryChemical BiologyPharmacotherapyUrologyChromatin
Publications per year
2002–2024
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 813 citations · Full text
Lineage-specific Tumours, Medicine, Immune Checkpoint Inhibitor +8
Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors
Yujia Dai, Yan Guo, Robin R. Frey et al. · Journal of Medicinal Chemistry · 2005 · 152 citations · Full text
Drug Target, Pharmacotherapy, Pharmaceutical Chemistry +17
Trifluoromethyl ketones as inhibitors of histone deacetylase
Robin R. Frey, Carol K. Wada, Robert B. Garland et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 147 citations · Full text
Histone Modifications, Chromatin, Medicinal Chemistry +10
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X<sub>L</sub> Inhibitor
Le Wang, George Doherty, Andrew S. Judd et al. · ACS Medicinal Chemistry Letters · 2020 · 127 citations · Full text
Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC)
Michael L. Curtin, Robert B. Garland, H. Robin Heyman et al. · Bioorganic & Medicinal Chemistry Letters · 2002 · 113 citations · Full text
Medicinal Chemistry, Succinimide Hydroxamic Acids, Biochemistry +8
Rows per page
1–5 of 20